AGC Biologics Invests in New Viral Vector Suspension


SEATTLE, May 17, 2022 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it is adding viral vector suspension technology and capacity for the…



Source link

Lascia un commento

Il tuo indirizzo email non sarà pubblicato.

 

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.